Intravitreal anti-vascular endothelial growth factor therapy with pegaptanib for advanced von Hippel-Lindau disease of the retina

Retina

Volumn 27, Issue 2, 2007, Pages 150-158

  Dahr, Sam S ^a   Cusick, Michael ^a   Rodriguez Coleman, Hanna ^a   Srivastava, Sunil K ^a   Thompson, Darby J ^b   Linehan, W Marston ^c   Ferris III, Frederick L ^a   Chew, Emily Y ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b EMMES CORPORATION   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCENT DYE; OFLOXACIN; PEGAPTANIB; POVIDONE IODINE; VASCULOTROPIN ANTIBODY;

ADULT; ARTICLE; CATARACT; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENDOPHTHALMITIS; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HEMANGIOMA; HUMAN; INJECTION; INTRAOCULAR HYPOTENSION; MALE; MEDICAL EXAMINATION; OPEN STUDY; OPTICAL COHERENCE TOMOGRAPHY; PATIENT COMPLIANCE; PILOT STUDY; RETINA; RETINA DETACHMENT; RETINA DISEASE; RETINA EXUDATE; RETINA MACULA EDEMA; RETINA TUMOR; THICKNESS; TREATMENT OUTCOME; TUMOR VOLUME; VISUAL ACUITY; VON HIPPEL LINDAU DISEASE;

ADULT; APTAMERS, NUCLEOTIDE; FEMALE; FLUORESCEIN ANGIOGRAPHY; HEMANGIOMA, CAPILLARY; HIPPEL-LINDAU DISEASE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RETINAL NEOPLASMS; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 33846969162     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318030a290     Document Type: Article

References (29)

1. Maher ER, Yates JRW, Harries R, et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990;77:1151-1163.
2. Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet 2003;361:2059-2067.
3. Friedrich CA. Von Hippel-Lindau syndrome. A pleomorphic condition. Cancer 1999;86:2478-2482.
4. Singh AD, Shields CL, Shields JA. von Hippel-Lindau disease. Surv Ophthalmol 2001;46:117-142.
5. Horton WA, Wong V, Eldridge R. Von Hippel-Lindau disease: clinical and pathological manifestations in nine families with 50 affected members. Arch Intern Med 1976;136:769-777.
6. Green JS, Bowmer MI, Johnson GJ. Von Hippel-Lindau disease in a Newfoundland kindred. CMAJ 1986;134:133-138, 146.
7. Whitson JT, Welch RB, Green WR. Von Hippel-Lindau disease: case report of a patient with spontaneous regression of a retinal angioma. Retina 1986;6:253-259.
8. Dollfus H, Massin P, Taupin P, et al. Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study. Invest Ophthalmol Vis Sci 2002;43:3067-3074.
9. McCabe CM, Flynn HW Jr, Shields CL, et al. Juxtapapillary capillary hemangiomas. Clinical features and visual acuity outcomes. Ophthalmology 2000;107:2240-2248.
10. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-1320.
11. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-275.
12. Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002;2:673-682.
13. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1-29.
14. Los M, Aarsman CJ, Terpstra L, et al. Elevated ocular levels of vascular endothelial growth factor in patients with von Hippel-Lindau disease. Ann Oncol 1997;8:1015-1022.
15. Chan CC, Vortmeyer AO, Chew EY, et al. VHL gene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma. Arch Ophthalmol 1999;117:625-630.
16. Harris AL. von Hippel-Lindau syndrome: target for antivascular endothelial growth factor (VEGF) receptor therapy. Oncologist 2000;5:S32-36.
17. Aiello LP, George DJ, Cahill MT, et al. Rapid and durable recovery of visual function in a patient with von Hippel-Lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology 2002;109:1745-1751.
18. Girmens JF, Erginay A, Massin P, et al. Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas. Am J Ophthalmol 2003;136:194-196.
19. Madhusudan S, Deplanque G, Braybrooke JP, et al. Antiangiogenic therapy for von Hippel-Lindau disease. JAMA 2004;291:943-944.
20. Wizigmann-Voos S, Breier G, Risau W, Plate KH. Upregulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 1995;55:1358-1364.
21. Gragoudas ES, Adamis AP, Cunningham ET, et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
22. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (pegaptanib) for the treatment of exudative age-related macular degeneration. Retina 2002;22:143-152.
23. Csaky K. Anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: promises and pitfalls. Ophthalmology 2003;110:879-881.
24. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005;293:1509-1513.
25. Ishida S, Usui T, Yamashiro K, et al. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003;44:2155-2162.
26. Usui T, Ishida S, Yamashiro K, et al. VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci 2004;45:368-374.
27. Webster AR, Maher ER, Moore AT. Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation. Arch Ophthalmol 1999;117:371-378.
28. Annesley WH Jr, Leonard BC, Shields JA, Tasman WS. Fifteen year review of treated cases of retinal angiomatosis. Trans Am Acad Ophthalmol Otolaryngol 1977;83:446-453.
29. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006;113:1001. e1-6. Epub: April 27, 2006.